Sugi Predict

Sugi Predict / Compounds / SCHEMBL738726

SCHEMBL738726

SCHEMBL738726

Cc1cc(O)c(Cl)cc1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 6/20 0.55
▸ TSHR P16473 5/20 0.55
▸ HPGD P15428 4/20 0.55
▸ LMNA P02545 2/20 0.48
▸ MCL1 Q07820 1/20 0.44
▸ ALDH1A1 P00352 6/20 0.43
▸ CYP3A4 P08684 4/20 0.43
▸ ALOX15 P16050 2/20 0.43
▸ MAPT P10636 2/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP2D6 P10635 1/20 0.43
▸ G6PD P11413 1/20 0.43
▸ CYP2C9 P11712 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ ALOX12 P18054 1/20 0.43
▸ MAPK1 P28482 1/20 0.43
▸ CYP2C19 P33261 1/20 0.43
▸ CCR6 P51684 1/20 0.43
▸ HIF1A Q16665 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6853371 0.86 HSD17B10 (0.60) HSD17B10TSHRHPGDLMNAMCL1
SCHEMBL4853924 0.86 HSD17B10 (0.60) HSD17B10TSHRHPGDLMNAMCL1
SCHEMBL13855825 0.86 HSD17B10 (0.52) HSD17B10TSHRHPGDLMNAMCL1
SCHEMBL8459523 0.86 TSHR (0.60) HSD17B10TSHRHPGDLMNAMCL1
SCHEMBL4062679 0.80 LMNA (0.58) HSD17B10TSHRHPGDLMNAALDH1A1
SCHEMBL22372546 0.79 HSD17B10 (0.46) HSD17B10TSHRHPGDLMNAMCL1
SCHEMBL10386838 0.79 CD44 (0.46) HSD17B10TSHRHPGDLMNAMCL1
SCHEMBL16250473 0.79 HSD17B10 (0.46) HSD17B10TSHRHPGDLMNAMCL1
SCHEMBL25843461 0.79 HSD17B10 (0.46) HSD17B10TSHRHPGDLMNAMCL1
SCHEMBL10827856 0.79 CD44 (0.52) HSD17B10TSHRHPGDLMNAMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 130 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080142370-A1 Aqueous, Acidic Solution and Method for Electrolytically Depositing Copper Coatings as Well as Use of Said Solution ATOTECH DEUTSCHLAND GMBH (DE) 2008-06-19 — — US claimed
EP-1651801-B1 AQUEOUS, ACIDIC SOLUTION AND METHOD FOR ELECTROLYTICALLY DEPOSITING COPPER COATINGS AS WELL AS USE OF SAID SOLUTION ATOTECH DEUTSCHLAND GMBH (DE) 2008-01-23 — — EP claimed
US-6989052-B1 Phase change ink printing process XEROX CORPORATION (US) 2006-01-24 — — US claimed
US-20060004123-A1 PHASE CHANGE INK PRINTING PROCESS XEROX CORPORATION 2006-01-05 — — US claimed
US-20260007625-A1 Compounds for the Treatment of Neuromuscular Disorders NMD PHARMA A/S (DK) 2026-01-08 — — US disclosed
EP-4587418-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD Pharma A/S (DK) 2025-07-23 — — EP disclosed
CN-116283503-B Method for separating phenol monomer from mixed phenol 煤炭科学技术研究院有限公司 2025-03-28 — — CN disclosed
WO-2024056865-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-03-21 — — WO disclosed
WO-2024056865-A1 COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS NMD PHARMA A/S (DK) 2024-03-21 — — WO disclosed
US-11760762-B2 Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors SIGNALRX PHARMACEUTICALS, INC. (US) 2023-09-19 — — US disclosed
CN-116283503-A Method for separating phenol monomer from mixed phenol 煤炭科学技术研究院有限公司 2023-06-23 — — CN disclosed
CN-113698279-B Method for separating and extracting 3, 5-xylenol from industrial xylenol 盐城工学院 2022-08-23 — — CN disclosed
US-4304735-A N-[4-(Tert-butyl)phenylsulfenyl]-N-alkylcarbamoyl fluoride compounds UNION CARBIDE CORPORATION (US) 1981-12-08 — — US disclosed
EP-0040741-A1 Process for the preparation of chloroformic-acid aryl esters BAYER AG (DE) 1981-12-02 — — EP disclosed
US-4193801-A DISSOLVING WATER-INSOLUBLE ADDITIVES IN A MELT OF ACID IMIDE OR DERIVATIVE CIBA-GEIGY AKTIENGESELLSCHAFT (CH) 1980-03-18 — — US disclosed
EP-0007987-A1 N-sulfenylated carbamoyloximino-1-methylthio butanes, process for their preparation and their use as insecticides BAYER AG (DE) 1980-02-20 — — EP disclosed
EP-0005780-A1 N,N'-asymmetrically substituted thio-bis-amines, process for their preparation and their use as insecticides, acaricides and nematocides BAYER AG (DE) 1979-12-12 — — EP disclosed
US-4146399-A DISSOLVING A TABLET CONTAINING PHOTOGRAPHIC ADDITIVE IN AQUEOUS COLLOID; COATING ON SUPPORT CIBA-GEIGY AG (CH) 1979-03-27 — — US disclosed
US-4140530-A DISPERSION OF FINELY DIVIDED ADDITIVE CIBA-GEIGY AG (CH) 1979-02-20 — — US disclosed
US-4137273-A INSECTICIDES, CHEMICAL INTERMEDIATES ZOECON CORPORATION (US) 1979-01-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11760762-B2 Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors CDK1, CDKN1A, CDKL1 HSD17B10 2529/4885TSHR 2452/4885HPGD 2967/4885
US-20260007625-A1 Compounds for the Treatment of Neuromuscular Disorders RYR1, CACNB1, CACNA1S HSD17B10 2320/4885TSHR 1006/4885HPGD 4471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.